PRLD Prelude Therapeutics

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:

Wells Fargo 18th Annual Healthcare Conference Boston
 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available . Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference.



H. C. Wainwright 25th Annual Healthcare Investment Conference
 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 p.m. ET. The live webcast is available . Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.



Morgan Stanley 21st Annual Global Healthcare Conference
 On Tuesday, September 12, at 4:55 p.m. ET, Dr. Vaddi and Dr. Huang will participate in a Fireside chat. The live webcast is available . Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.
  

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.

For more information, visit our and follow us on and .

Investor Contact: 

Lindsey Trickett 

Vice President, Investor Relations 

240.543.7970 

Media Contact: 

Helen Shik

Shik Communications

617.510.4373



EN
29/08/2023

Underlying

PRLDPrelude Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prelude Therapeutics

 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Receives FDA Clearance of Investigational New Dru...

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective J...

February 3, 2026 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prog...

December 6, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and ...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 20...

November 12, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Strategic Business Update Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third quarter of 2028 if Incyt...

November 4, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte ...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milesto...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch